PMV Pharmaceuticals, an early stage biotech developing targeted therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company's lead candidate, PC14586, is designed to potently and selectively correct p53 misfolding caused by a specific p53 mutation while sparing wild-type p53. The company is initially pursuing a tumor-agnostic development strategy and submitted an IND for PC14586 in August 2020, with a Phase 1/2 trial planned for the 2H20.
The Cranbury, NJ-based company was founded in 2013 and plans to list on the Nasdaq under the symbol PMVP. PMV Pharmaceuticals filed confidentially on June 26, 2020. Goldman Sachs, BofA Securities, Cowen and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
